Epi CanaryEpi Canary
  • Home
  • Feed
  • Synthesis
  • Assessments
  • Scopes
  • Reliability
  • Sources
Epi Canary — Epidemic IntelligenceEvidence-led epidemic intelligence. Source-attributed evidence.
Arcede logoMade by Arcede

Public note

For situational awareness and research transparency. Not medical advice.

Novel Pathogen Detectionactive

At least one additional case of XDR Shigella sonnei carrying BOTH blaDHA-1 (cephalosporinase) and blaCTX-M-15 (ESBL) — the dual-cephalosporinase phenotype first reported in two epidemiologically unlinked LA patients (Yang et al., Antimicrobial Stewardship & Healthcare Epidemiology, CIDRAP 2026-01-14) — will be reported in any T1 source (CDC, MMWR, peer-reviewed journal, ECDC, GLASS) by 2026-07-21.

System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.

Substantial confidence

Confidence in this assessment
60%

Multiple lines of evidence are aligned, though the assessment remains provisional. Based on 5 linked evidence items and assessed against 90D.

Assessed through 90D·5 linked evidence items·Tracking since Apr 20, 2026

02

How this assessment will be evaluated

The criteria the system uses to determine whether this assessment is borne out by the stated horizon.

Automated

Method

Evidence Match

The condition the system checks for when evaluating this assessment.

Minimum source quality

T1Primary Institutional

Evidence must meet or exceed this credibility tier to count toward evaluation.

Required terms

dual-cephalosporinaseepidemiologicallycephalosporinaseantimicrobial

03

Evidence quality mix

Tracking since Apr 20, 2026.

T25
▸Integrity referencesCryptographic hashes for verification

Registration

06

Scope synthesis

The current analyst narrative for this scope.

Open synthesis →

AMR evidence coverage critically degraded this cycle; two hypotheses resolve in 5 days without supporting data; PubMed failure is the primary bottleneck.

07

Evidence linked to this assessment

5 linked items.

XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026 Title: "Emergence of Extensively Drug-Resistant

Currently interpreted as supporting evidence for 13 tracked assessments.

T2https://www.cdc.gov/mmwr/volumes/75/wr/mm7515a1.htmsupports
Apr 20, 2026
Shigellosis: USA, increasing incidence, antimicrobial resistance, 2023. The CDC is monitoring th

Currently interpreted as supporting evidence for 6 tracked assessments.

T2https://www.promedmail.org/?alert=8732316supports
Apr 20, 2026
Shigellosis: USA, increasing incidence, antimicrobial resistance, 2023. The infection spreads ea

Currently interpreted as supporting evidence for 6 tracked assessments.

T2https://www.promedmail.org/?alert=8732316supports
Apr 20, 2026
Shigellosis: USA, increasing incidence, antimicrobial resistance, 2023. This resistant strain is

Currently interpreted as supporting evidence for 6 tracked assessments.

T2https://www.promedmail.org/?alert=8732316supports
Apr 20, 2026
Shigellosis: USA, increasing incidence, antimicrobial resistance, 2023. The CDC has issued an al

Currently interpreted as supporting evidence for 6 tracked assessments.

T2https://www.promedmail.org/?alert=8732316supports
Apr 20, 2026

Integrity anchor

Brier 0.202

19 resolved novel pathogen detection predictions.